For Immediate Release

3D BioFibR Enters the Bioprinting and 3D Cell Culture Market
with the Launch of Two CollaFibR™ Tissue Engineering Products
June 26, 2023 – HALIFAX, Nova Scotia - 3DBioFibR, a leading innovator in tissue engineering, announced
today it is launching two new collagen fiber products, μCollaFibR™ (pronounced micro-CollaFibR™) andCollaFibR™ 3D scaffold. Made using 3D BioFibR’s proprietary and new dry-spinning technology to create
collagen fibers at commercial scales, these off-the-shelf products offer significant advantages for tissueengineering and tissue culture applications and are now available for sale, to the scientific and medical
communities at www.3DBioFibR.com.
μCollaFibR™ is a bioink additive for use in 3D bioprinting of tissue and organ models in a laboratory
setting. μCollaFibR mimics the body’s natural cellular scaffold and acts like a biological rebar in bioinks
used to print living tissues. When added to bioinks, μCollaFibR improves the mechanical durability ofprinted tissues so multiple cell types can be assembled layer-by-layer to produce highly functional tissueand organ models.
“3D bioprinting is the future of regenerative medicine and it’s exciting to offer μCollaFibR to enhance
the capabilities in 3D bioprinting,” said Kevin Sullivan, CEO of 3D BioFibR. “We all want to imagine afuture where doctors could just print a kidney, using cells from the patient, instead of having to find adonor match. Our collagen fibers represent a significant improvement over existing scaffolds used in 3D
bioprinting, moving the field closer to this reality.”
The CollaFibR™ scaffold for 3D cell culture allows researchers to study cellular reactions in a more
physiologically relevant 3D environment, compared to traditional 2D cultures. The advantage of theCollaFibR scaffold is that it uses GMP type 1 collagen to produce a consistent collagen fiber matrix that
resembles the biomechanical and biochemical properties of natural cellular environments.
Sullivan added, “Our CollaFibR scaffold allows
cells to grow and interact with the surrounding
cellular scaffold in 3D, making it ideal for creating
realistic tissue constructs for laboratory testing ofnew drugs and tissue models. Plus, our standardwell plate dimensions are compatible with
automated equipment for high throughput
compound screening and advanced microscopy.”
About CollagenIn the human body, collagen plays a crucial role as
the primary structural element of theextracellular matrix. This matrix forms a
supportive framework for tissues, holding them
together and imparting mechanical durability. Collagen fibers also constitute around 30% of the total
protein content in the body. Although collagen has widespread applications in the biomedical field,
researchers and clinicians typically utilize digested collagen in its monomeric form (individual proteins).
While monomeric collagen serves many valuable functions, there has been a persistent effort, for over
five decades, to reassemble these individual proteins into fibers that closely resemble natural collagenfibers found in the body, in terms of appearance, structure, and function.

For Immediate Release
About 3D BioFibR Inc.
3D BioFibR produces high value collagen fibers at commercial scales for a variety of tissue engineeringand medical applications. The Company’s proprietary dry-spinning process produces fibers that are bestin-class from a strength, diameter, and quality perspective, recreating the natural appearance, structure,and function of collagen fibers. This manufacturing process is at least 3,600x faster than competing
manufacturing processes making its collagen fibers accessible for an increasing number of bio-medical
applications in the growing tissue engineering market. For more information, visit www.3DBioFibR.com.
##
This news release contains “forward-looking statements,” which reflect the current expectations of theCompany’s management for future growth, results of operations, performance and business prospects.
Forward-looking statements involve significant known and unknown risks, uncertainties andassumptions.
INVESTOR RELATIONSKevin Sullivan, CEO
3D BioFibR Inc.
E: Info@3DBioFibR.com
W: www.3DBioFibR.com

MEDIA CONTACTJennifer Cameron
Communications Advisor
E: jennifercameronpr@gmail.com
T: 902-209-4704